JMP Securities reiterated coverage on Altimmune with a new price target

6/30/21 6:54:32 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

JMP Securities reiterated coverage of Altimmune with a rating of Market Outperform and set a new price target of $31.00 from $53.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALT

Date	Price Target	Rating	Analyst
2/28/2025		Mkt Perform	William Blair
1/8/2025	$18.00	Buy	Stifel
11/12/2024	$26.00	Buy	UBS
4/29/2024		Buy → Neutral	Guggenheim
1/24/2024	$13.00	Neutral	Goldman
3/22/2023	$20.00 → $6.00	Buy → Neutral	Goldman
12/1/2022	$20.00	Buy	Goldman
12/29/2021	$30.00	Buy	Jefferies